KRMN Q1 2026 Earnings EPS Misses Estimates Stock Declines Sharply OBIO Q1 2026 Earnings NarrowerthanExpected Loss Highlights Cost Discipline in PreRevenue Phase MiNK Therapeutics Q1 2026 Earnings Narrowed Loss Exceeds Expectations Amid Clinical Progress ADPT Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Surprise FSTR Q1 2026 Earnings Stunning Profitability Surge as EPS Swings to 014 from Expected Loss Moleculin Biotech MBRX Holds Steady at 239 as Trading Remains Flat BeOne Medicines ONC Edges Higher Amid Sector Volatility Key Levels in Focus John Wiley Sons WLY Edges Higher Modest Gains Amid Consolidation Phase Deswell Industries Surges 68 Potential Breakout or Resistance Test FMBH Q1 2026 Earnings Strong EPS Beat Fails to Boost Sentiment